Literature DB >> 10900255

Disposition of glutathione conjugates in rats by a novel glutamic acid pathway: characterization of unique peptide conjugates by liquid chromatography/mass spectrometry and liquid chromatography/NMR.

A E Mutlib1, J Shockcor, R Espina, N Graciani, A Du, L S Gan.   

Abstract

With the advent of liquid chromatography/mass spectrometry and liquid chromatography/NMR, it has become easier to characterize metabolites that were once difficult to isolate and identify. These techniques have enabled us to uncover the existence of an alternate pathway for the disposition of glutathione adducts of several structurally diverse compounds. Studies were carried out using acetaminophen as a model compound to investigate the role of the glutamic acid pathway in disposition of the glutathione adducts. Although the mercapturic acid pathway was the major route of degradation of the glutathione adducts, it was found that the conjugation of the glutathione, cysteinylglycine, and cysteine adducts of acetaminophen with the gamma-carboxylic acid of the glutamic acid was both interesting and novel. The coupling of the glutathione adduct and the products from the mercapturic acid pathway with the glutamic acid led to unusual peptide conjugates. The natures of these adducts were confirmed unequivocally by comparisons with synthetic standards. This pathway (addition of glutamic acids) led to larger peptides, in contrast to the mercapturic acid pathway, in which the glutathione adducts are broken down to smaller molecules. The enzyme responsible for the addition of glutamic acid to the different elements of the mercapturic acid pathway is currently unknown. It is postulated that the gamma-carboxylic acid is activated (perhaps by ATP) before enzymatic addition to the alpha-amino group of cysteine or glutamate takes place. The discovery of these peptide conjugates of acetaminophen represents a novel disposition of glutathione adducts of compounds. The formation of such conjugates may represent yet another pathway by which drugs could produce covalent binding via their reactive intermediates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900255

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

2.  Sulphation of acetaminophen by the human cytosolic sulfotransferases: a systematic analysis.

Authors:  Akihiro Yamamoto; Ming-Yih Liu; Katsuhisa Kurogi; Yoichi Sakakibara; Yuichi Saeki; Masahito Suiko; Ming-Cheh Liu
Journal:  J Biochem       Date:  2015-06-11       Impact factor: 3.387

3.  Effects of acetaminophen in Brassica juncea L. Czern.: investigation of uptake, translocation, detoxification, and the induced defense pathways.

Authors:  Bernadett Bartha; Christian Huber; Rudolf Harpaintner; Peter Schröder
Journal:  Environ Sci Pollut Res Int       Date:  2010-06-24       Impact factor: 4.223

4.  Integrating Network Pharmacology and Metabolomics to Elucidate the Mechanism of Action of Huang Qin Decoction for Treament of Diabetic Liver Injury.

Authors:  Xiaomin Xu; Cheng Fang; Yu Wang; Fang Lu; Shumin Liu
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

5.  Metabolism of acetaminophen (paracetamol) in plants--two independent pathways result in the formation of a glutathione and a glucose conjugate.

Authors:  Christian Huber; Bernadett Bartha; Rudolf Harpaintner; Peter Schröder
Journal:  Environ Sci Pollut Res Int       Date:  2009-01-15       Impact factor: 4.223

6.  Liquid chromatography-electrospray tandem mass spectrometry investigations of fragmentation pathways of biliary 4,4'-methylenedianiline conjugates produced in rats.

Authors:  Kan Chen; Tammy R Dugas; Richard B Cole
Journal:  Anal Bioanal Chem       Date:  2008-03-30       Impact factor: 4.142

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.